Published in final edited form as:

Biochemistry. 2008 September 2; 47(35): 9051–9053. doi:10.1021/bi801159x.

Crystal structure of type 2 Isopentenyl Diphosphate Isomerase from *Thermus thermophilus* in complex with inorganic pyrophosphate†

Jérôme de Ruyck^{1,*}, Jenny Pouyez¹, Steven C. Rothman², C. Dale Poulter², and Johan Wouters^{1,*}

¹Department of Chemistry, University of Namur, Namur, Belgium

²Department of Chemistry, University of Utah, Salt Lake City, Utah 84112, USA

Abstract

The N-terminal region is stabilized in the crystal structure of *T. thermophilus* type 2 IPP isomerase in complex with inorganic pyrophosphate; providing new insights about the active site and the catalytic mechanism of the enzyme. The PPi moiety is located near the conserved residues, H10, R97, H152, Q157, E158 and W219, and the flavin cofactor. The putative active site of IDI-2 provides interactions for stabilizing a carbocationic intermediate similar to those that stabilize the intermediate in the well-established protonation/deprotonation mechanism of IDI-1.

Graphical abstract

Isopentenyl diphosphate isomerase (IDI) is a key enzyme in the isoprenoid biosynthetic pathway, which produces several classes of essential compounds in humans. IDI catalyzes the required isomerization of isopentenyl diphosphate (IPP) to dimethylallyl diphosphate (DMAPP) in the mevalonate entry into the isoprenoid pathway and serves to balance the pools of IPP and DMAPP in the methylerythritol phosphate entry.^{1, 2}

Two isoforms of IPP isomerase, IDI-1 and IDI-2, have been identified. IDI-1 is a zinc metalloprotein which was first characterized over 40 years ago.^{3,4, 5} The structure of IDI-1 is

†JdR is grateful for financial support from the Belgian Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture (FRIA). Financial support by NIH grant GM 25521 (CDP) and by FNRS (IISN n° 4.4505.00) for access to the ESRF synchrotron is acknowledged.

*Corresponding authors: Jérôme de Ruyck, Johan Wouters, Tel +32 81 72 4569; Fax +32 81 72 4530; jeromederyck@fundp.ac.be, johan.wouters@fundp.ac.be.

Supporting Information Available for overexpression, purification, crystallization, X-ray crystallographic data collection, structure refinement and molecular modeling free of charge via the Internet at <http://pubs.acs.org>.

known, and its mechanism of action has been studied extensively.⁶⁻⁸ The IDI-2 isoform was discovered recently.⁹ The enzyme is a flavoprotein that requires FMN, a reducing agent (typically NADPH), and a divalent metal. IDI-2 is an essential enzyme for those pathogenic microorganisms, such as some strains of *Streptococcus* and *Staphylococcus*, that rely on the mevalonate pathway for isoprenoid biosynthesis.¹⁰ Thus, IDI-2 is a logical target for the design of anti-infectious agents.

There are various proposals for the role of the flavin, although recent reports suggest that the cofactor participates in a protonation-deprotonation mechanism.¹¹⁻¹⁴ A crystal structure of the *Bacillus subtilis* protein (*bs*-IDI2) was reported in 2003 (PDB ID: 1P0N).¹⁵ In 2004, two structures of IDI-2 from *Thermus thermophilus* (*tt*-IDI2), a thermophilic microorganism, were solved (PDB ID: 1VCF and 1VCG).¹⁶ The proteins crystallized as typical D α 8 β 8 TIM-barrels and one molecule of FMN was bound per monomer. Nevertheless, electron density was not detected for several amino acids at the active site due to their conformational flexibility. We obtained an X-ray structure of *tt*-IDI2 in 2005 and faced the same problem with flexibility. We therefore combined the available structural information to construct a model of the complete structure of IDI-2 (PDB ID: 2IOW). Docking studies with this model helped us to identify a putative active site.¹⁷ In the present report, we present an experimental X-ray structure of IDI-2 from *Thermus thermophilus* in complex with inorganic pyrophosphate (PP_i) (PDB ID: 3DH7), which facilitates visualization of electron density for a conserved region at the N-terminus of the protein. Analysis of the electron density maps and molecular modeling with this more complete structure presents new perspectives for the mechanisms of catalysis and inhibition of IDI-2.

Overexpression, purification and crystallization of *tt*-IDI2 were adapted from the previous experimental procedures¹⁷ and are described in the Supporting Information. The protein also crystallizes as a typical α 8 β 8 TIM-barrel (Figure 1A). Four monomers are assembled as a symmetrical *D*₄ open cage-like structure in the asymmetric unit, similar to 1VCG. Main crystallographic details are given in table 1.

As previously described¹⁴, one molecule of FMN is bound per monomer and located in the standard phosphate binding (SPB) region of the TIM barrel. The phosphate moiety of the cofactor is stabilized by interactions with Gly 264, Tyr 266 and Ala 285 while the isoalloxazine ring contacts with Leu 11, Ala 65, Met 66, Ser 95, Asn 123, Lys 187 and Val 189. The *si*-face of FMN faces the indole moiety of Trp 219 and is further stabilized through an edge-to-face interaction.

After refinement of the position of the cofactor, we observed an additional electron density located near the flavin that was attributed to inorganic pyrophosphate (PP_i). The structure of the IDI-2-flavin-PP_i complex (Figure 1B) allows us to identify conserved residues in the putative active site. PP_i is stabilized by electrostatic interactions with conserved residues His 10, Arg 97 and His 152 and is located near Gln 157, Glu 158 and FMN. It is noteworthy that comparisons of the available crystal structures for IDI-2 reveals two different conformations for the aromatic Trp 219 residue. In the apo-protein the indole ring of tryptophane stacks with the isoalloxazine ring (1VCF) (Figure 2A), the N-terminal segment is disordered, and residues 1 to 22 are not seen. When PP_i is bound, Trp 219 interacts with FMN through an

edge-to-face interaction, and additional N-terminal residues 9-22 are visible in the electron density map (Figure 2B). We conclude that the enzyme exists in an “open” form in the absence of substrate. Substrate binding triggers a conformational change to a “closed” form where the N-terminal residues form a lid over the putative active site that shield it from bulk water.

Recent reports for irreversible inhibitors of IDI-2 demonstrated that the compounds covalently modified the isoalloxazine ring of reduced FMN.¹⁸⁻²⁰ Based on our new crystallographic structure, we modeled the binding of oIPP to the IDI-2-FMN complex; oIPP is a potent active-site directed irreversible inhibitor. We observed (Figure 3A) that the epoxide ring of oIPP is located just above the N5 of FMN (distance N5-C_{asym} = 4.1 Å). This binding mode is fully compatible with an irreversible inhibition where N5 acts as the nucleophile after epoxide ring is activated by protonation. Support for this model was achieved by treating crystals of IDI-2-FMN with 100mM Na₂S₂O₄ followed by 10mM oIPP. Upon addition of Na₂S₂O₄, we observed that the yellow color vanished, indicating that FMN was reduced. Due to the ambient O₂, the flavin slowly reoxidized and yellow color of the crystals reappeared. However, when the reduced crystals were soaked with oIPP, they remained colorless; suggesting that flavin is locked in its reduced form and that oIPP chemically modified the isoalloxazine ring (Figure 3B).

This observation is in agreement with UV-vis spectral observations in solution for epoxide-mediated inactivation of IDI-2.^{12, 14}

Those new results are consistent with the hypothesis that IDI-1 and 2 catalyze isomerization by similar protonation/deprotonation mechanisms (Figure 3C).^{12, 18-20} The putative carbocationic intermediate, generated after the protonation step, could be stabilized by π -cation interactions with the isoalloxazine ring in FMN and the indole ring in W219. Similar interactions between the carbocation and a conserved tryptophan are thought to be important in the protonation-deprotonation reaction catalyzed by IDI-1.⁷

In order to validate the binding mode of oIPP in the active site of IDI-2, experimental X-ray data collections are now planned. A crystal structure of the complex IDI-2FMNoIPP would provide a strong argument in favor of the hypotheses about the catalytic and the inhibition mechanisms presented here.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Authors want to thank all the FIP-BM30A staff for their assistance during the data collection. Figures were prepared using PyMOL software.²¹

References

1. Rohmer M. Nat Prod Rep. 1999; 16:565–574. [PubMed: 10584331]
2. Rohdich F, Bacher A, Eisenreich W. Bioorg Chem. 2004; 32:292–308. [PubMed: 15381396]

3. Agranoff BW, Eggerer H, Henning U, Lynen F. J Biol Chem. 1960; 235:326–332. [PubMed: 13792054]
4. Ramos-Valdivia AC, van der Heijden R, Verpoorte R, Camara B. Eur J Biochem. 1997; 249:161–170. [PubMed: 9363768]
5. Carrigan CN, Poulter CD. J Am Chem Soc. 2003; 125:9008–9. [PubMed: 15369345]
6. Wouters J, Oudjama Y, Ghosh S, Stalon V, Droogmans L, Oldfield E. J Am Chem Soc. 2003; 125:3198–3199. [PubMed: 12630859]
7. Wouters J, Oudjama Y, Barkley SJ, Tricot C, Stalon V, Droogmans L, Poulter CD. J Biol Chem. 2003; 278:11903–11908. [PubMed: 12540835]
8. Durbecq V, Sainz G, Oudjama Y, Clantin B, Bompard-Gilles C, Tricot C, Caillet J, Stalon V, Droogmans L, Villeret V. Embo J. 2001; 20:1530–1537. [PubMed: 11285217]
9. Kaneda K, Kuzuyama T, Takagi M, Hayakawa Y, Seto H. Proc Natl Acad Sci U S A. 2001; 98:932–937. [PubMed: 11158573]
10. Kuzuyama T, Seto H. Nat Prod Rep. 2003; 20:171–183. [PubMed: 12735695]
11. Rothman SC, Helm TR, Poulter CD. Biochemistry. 2007; 46:5437–5445. [PubMed: 17428035]
12. Hoshino T, Tamegai H, Kakinuma K, Eguchi T. Bioorg Med Chem. 2006; 14:6555–6559. [PubMed: 16793276]
13. Hemmi H, Ikeda Y, Yamashita S, Nakayama T, Nishino T. Biochem Biophys Res Commun. 2004; 322:905–910. [PubMed: 15336549]
14. Rothman SC, Johnston JB, Lee S, Walker JR, Poulter CD. J Am Chem Soc. 2008; 130:4906–4913. [PubMed: 18345677]
15. Steinbacher S, Kaiser J, Gerhardt S, Eisenreich W, Huber R, Bacher A, Rohdich F. J Mol Biol. 2003; 329:973–982. [PubMed: 12798687]
16. Wada T, Park SY, Tame RH, Kuramitsu S, Yokoyama S. Unpublished results. 2003
17. de Ruyck J, Rothman SC, Poulter CD, Wouters J. Biochem Biophys Res Commun. 2005; 338:1515–1518. [PubMed: 16269131]
18. Johnston JB, Walker JR, Rothman SC, Poulter CD. J Am Chem Soc. 2007; 129:7740–7741. [PubMed: 17547410]
19. Thibodeaux CJ, Mansoorabadi SO, Kittleman W, Chang WC, Liu HW. Biochemistry. 2008; 47:2547–2558. [PubMed: 18229948]
20. Walker JR, Rothman SC, Poulter CD. J Org Chem. 2008; 73:726–729. [PubMed: 18088143]
21. DeLano, WL. The PyMOL Molecular Graphics System, 0.99rev8. DeLano Scientific; San Carlos, CA, USA: 2002.

Figure 1.

A) Typical $\alpha 8 \beta 8$ TIM-barrel fold of one monomer. Red segments are flexible regions (9-22 and 223-234) observed in this structure and absent in 1P0N and 1VCG. Flavin (yellow, A and B), is located at the end of the barrel and near PPi (orange, B). B) Extra electron density (blue contour, $2F_o - F_c$, 1σ) corresponding to PPi is observed near the flavin and conserved histidines His 10 and His 152. The indole group of W219 interacts with isoalloxazine moiety through an edge-to-face interaction, and the N-terminal segment, which contains His 10, is well-folded.

Figure 2.

A) In the IDI-2-FMN complex Trp219 (green) stacks with the isoalloxazine ring (yellow). Some parts of the enzyme are very flexible and cannot be observed by X-ray diffraction (red circles). We assume that this is the opened state of IDI-2. B) In the IDI-2-FMN-PP_i complex Trp219 interacts with FMN through an edge-to-face interaction, the global fold of the enzyme is stabilized and the previously missing parts are observed. This corresponds to a closed state triggered by the substrate binding.

Figure 3.

A) Binding mode of oIPP (light blue) into the putative active site of IDI-2. The epoxide ring is located in order to chemically modify the N5 nitrogen of the isoalloxazine ring (yellow).

B) Chemical reduction of IDI-2 crystals followed by soaking of oIPP indicates that the flavin cofactor is locked in its reduced form. This is in good agreement with a covalent bond between N5 of flavin and the irreversible inhibitor.

C) The protonation/deprotonation mechanism for isomerization catalyzed by IDI-1 and 2. Aromatic π - π interactions in IDI-1 and 2 can stabilize the carbocationic intermediate. Reduced FMN could act as the proton donor and/or proton acceptor in the reaction.

Table 1
Data collection and refinement statistics

Space group	P3 ₂	Completeness ^a (%)	97.3 (84.0)
Cell dimensions (Å)	<i>a</i> =142.5 <i>b</i> =142.5 <i>c</i> =109.7	<i>R</i> _{merge} ^a (%)	12.4 (32.0)
Wavelength (Å)	0.9797	<i>I</i> / σ ^a (I)	7.1 (3.4)
Highest resolution (Å)	2.97	<i>R</i> _{work} / <i>R</i> _{free} ^b (%)	21.1/29.2
Observed reflections	291921	R.M.S.D.	
Unique reflections	49971	Bond lengths (Å) Bond angles (°)	0.02 2.02
PDB ID: 3 DH7			

^a Values listed in parentheses are for the highest resolution shell (3.15-2.97)

^b Free test subset represents 5% of total unique reflections.